Sahajanand Medical Technologies IPO: Complete Analysis, Financial Performance, Valuation & Investment Strategy
Sahajanand Medical Technologies IPO Key Issue Details
The Sahajanand Medical Technologies IPO is a 100% Offer for Sale (OFS) issue of 1,38,22,116 equity shares with a face value of ₹1 each, aggregating up to ₹475.48 Crore. Since the IPO is completely an OFS, all proceeds generated will go directly to the selling promoters and corporate PE investors, and the company will not receive fresh capital from the offering.
| Issue Parameter | Details & Specifications |
|---|---|
| IPO Open Date | Thursday, October 15, 2026 |
| IPO Close Date | Monday, October 19, 2026 |
| Price Band | ₹327 to ₹344 per equity share |
| Face Value | ₹1 per equity share |
| Total Issue Size | 1,38,22,116 Shares (Aggregating up to ₹475.48 Cr) |
| Offer for Sale (OFS) Component | 1,38,22,116 Shares (Aggregating up to ₹475.48 Cr) |
| Market Lot Size | 43 Shares per application |
| Pre-Issue Equity Shareholding | 10,16,46,778 Equity Shares |
| Post-Issue Equity Shareholding Base | 10,16,46,778 Equity Shares |
| Market Capitalization (Upper Band) | ₹3,496.65 Crore |
| Stock Exchanges Listing | BSE (Bombay Stock Exchange) & NSE (National Stock Exchange) |
| Book Running Lead Managers (BRLMs) | Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities, Nuvama Wealth Management |
| Registrar to the Offer | MUFG Intime India Pvt. Ltd. (Link Intime) |
2. Important Timeline & Event Schedule
Investors planning to apply for the Sahajanand Medical Technologies IPO should track the following key tentative schedule dates for bidding, allotment status, refunds, and exchange listing:
| IPO Schedule Event | Tentative Date |
|---|---|
| IPO Opening Date | Thursday, October 15, 2026 |
| IPO Closing Date | Monday, October 19, 2026 |
| Basis of Allotment Finalization | Wednesday, October 21, 2026 |
| Initiation of Refunds / Unblocking Funds | Thursday, October 22, 2026 |
| Credit of Equity Shares to Demat Accounts | Thursday, October 22, 2026 |
| Official Stock Exchange Listing Date | Friday, October 23, 2026 |
3. Category Reservations, Lot Sizes & Bidding Limits
Bids can be submitted in multiples of 43 equity shares. The net public issue is reserved as follows: not more than 50% for QIBs, not less than 35% for Retail Individual Investors, and not less than 15% for Non-Institutional Investors (NIIs/HNIs).
| Investor Category | Minimum Lots | Total Shares | Minimum Investment Amount (₹) |
|---|---|---|---|
| Retail Individual (Minimum) | 1 Lot | 43 Shares | ₹14,792 |
| Retail Individual (Maximum) | 13 Lots | 559 Shares | ₹1,92,296 |
| Small HNI / sNII (Minimum) | 14 Lots | 602 Shares | ₹2,07,088 |
| Small HNI / sNII (Maximum) | 67 Lots | 2,881 Shares | ₹9,91,064 |
| Big HNI / bNII (Minimum) | 68 Lots | 2,924 Shares | ₹10,05,856 |
4. Business Profile, R&D Capabilities & Global Reach
Incorporated in October 2001, Sahajanand Medical Technologies Limited (SMT) is a leading global medical device company specializing in cardiovascular intervention products. SMT designs, manufactures, and markets advanced medical devices tailored for vascular and structural heart therapies.
SMT’s core product lines serve critical areas of interventional cardiology and vascular repair:
- Vascular Intervention Products: Drug-eluting stents (DES), bare metal stents, coronary balloon catheters, drug-coated balloons (DCBs), renal stents, and peripheral interventional devices. flagship brands include Supraflex Cruz.
- Structural Heart Intervention Devices: Transcatheter aortic valve implantation (TAVI) systems, structural occluders, and cardiac repair technologies under flagship brands like Hydra and Cocoon.
- R&D Infrastructure & Global Patents: Operates two dedicated R&D centers in India and Thailand. As of June 30, 2026, SMT holds 119 granted global patents, 78 pending patent applications, and 5 Indian design registrations.
- Manufacturing Capabilities & Distribution: Three precision manufacturing facilities (two in India and one in Thailand). SMT markets its products across 77 countries through direct sales, hybrid models, and distribution networks in India, Europe, Asia, and Latin America.
5. Restated Consolidated Financial Performance
Below is the detailed restated financial trajectory of Sahajanand Medical Technologies Limited over recent financial reporting periods (amounts in ₹ Crore):
| Financial Metric | Q1 FY27 (June 30, 2026) | FY26 (Mar 31, 2026) | FY25 (Mar 31, 2025) | FY24 (Mar 31, 2024) |
|---|---|---|---|---|
| Total Assets | ₹1,309.00 Cr | ₹1,276.43 Cr | ₹1,094.90 Cr | ₹970.58 Cr |
| Total Revenue / Income | ₹354.33 Cr | ₹1,218.73 Cr | ₹1,035.96 Cr | ₹908.59 Cr |
| Operating EBITDA | ₹48.58 Cr | ₹170.66 Cr | ₹128.02 Cr | ₹110.05 Cr |
| Profit After Tax (PAT) | ₹15.09 Cr | ₹69.08 Cr | ₹25.15 Cr | -₹7.35 Cr |
| Net Worth | ₹631.72 Cr | ₹616.05 Cr | ₹545.23 Cr | ₹526.30 Cr |
| Reserves & Surplus | ₹706.86 Cr | ₹692.48 Cr | ₹580.71 Cr | ₹556.57 Cr |
| Total Borrowings | ₹320.63 Cr | ₹269.53 Cr | ₹224.96 Cr | ₹175.27 Cr |
Financial Trend Note: Operational revenue grew by 18% from ₹1,035.96 Crore in FY25 to ₹1,218.73 Crore in FY26. Net profit (PAT) grew by 175% from ₹25.15 Crore to ₹69.08 Crore in FY26, reflecting strong margin expansion following operating turnarounds after FY24 losses.
6. Key Performance Indicators (KPIs) & Valuation Ratios
| KPI & Valuation Parameter | Q1 FY27 Value | FY26 (Full Year) |
|---|---|---|
| Pre-IPO EPS (₹) | – | ₹6.80 |
| Post-IPO EPS (₹) | – | ₹5.94 |
| Pre-IPO P/E Ratio (x) | – | 50.59x |
| Post-IPO P/E Ratio (x) | – | 57.91x |
| Return on Equity (ROE) | 2.07% | 10.35% |
| Return on Capital Employed (ROCE) | 3.16% | 11.57% |
| Debt to Equity Ratio | 0.33x | 0.27x |
| Net Asset Value (NAV per share) | ₹64.35 | ₹62.76 |
| Price to Book (P/B) Ratio | 5.48x | – |
7. Live Grey Market Premium (GMP) & Estimated Listing Analysis
Grey market sentiment shows steady baseline interest for SMT IPO in early trading sessions:
- Latest Recorded GMP: +₹40.00 per share (11.63%)
- Upper Price Band: ₹344.00
- Estimated Listing Price: ₹384.00 per share (Upper Price ₹344 + Live GMP ₹40)
- Expected Listing Profit Per Lot: ₹1,720 (43 Shares × ₹40 GMP)
- Retail Subject to Sauda: ₹1,300 per application
- Small HNI Subject to Sauda: ₹18,200 per application
Day-Wise GMP Movement:
- October 11, 2026: ₹40.00 (Initial sentiment base)
- October 12, 2026 (05:37 PM): ₹40.00 (Stable holding trend)
8. Promoters, Offer for Sale Breakdown & Shareholding
The company promoters are Bhargav Dhirajlal Kotadia, Dhirajlal Vallabhbhai Kotadia, Priyanka Dhirajlal Cohen, and Shree Hari Trust. Pre-issue promoter group holding stands at 40.82%, which will dilute to 36.20% post-issue.
| Selling Shareholder Name | Category | Shares Offered | Estimated Amount (₹ Cr) |
|---|---|---|---|
| Shree Hari Trust | Promoter | 27,00,000 Shares | ₹92.88 Cr |
| Dhirajkumar Savjibhai Vasoya | Promoter Group | 20,00,000 Shares | ₹68.80 Cr |
| Samara Capital Markets Holding Ltd. | Corporate PE Investor | 64,79,063 Shares | ₹222.88 Cr |
| Kotak Pre-IPO Opportunities Fund | Corporate Investor | 13,07,875 Shares | ₹44.99 Cr |
| NHPEA Sparkle Holding B.V. | Corporate Investor | 13,35,178 Shares | ₹45.93 Cr |
| Total Offer for Sale (OFS) | – | 1,38,22,116 Shares | ₹475.48 Cr |
9. Investment Analysis: Key Strengths vs Risk Factors
Key Competitive Strengths:
- High Barrier MedTech Industry: Stents and structural heart valves require intensive clinical trials, stringent global regulatory approvals, and specialized precision manufacturing.
SEBI Compliance Note: ipoind.com is an independent financial analytics and primary market research portal provided solely for educational and informational purposes. We are NOT a SEBI-registered Investment Advisor or Research Analyst. Financial market investments, equity securities, and Initial Public Offerings (IPOs) carry inherent market risks.
Grey Market Premium (GMP) Notice: Figures regarding Grey Market Premium (GMP), Kostak rates, and subject-to-sauda deals reflect unofficial, unregulated over-the-counter market sentiment. These figures do not guarantee exchange listing prices or actual trading outcomes. Always evaluate official Draft Red Herring Prospectus (DRHP / RHP) documents filed with BSE/NSE and consult a certified financial advisor prior to executing financial bidding decisions.